Today's Rundown As Brexit nears, Britain's drugs, devices and pricing regulators seek the exit Biotech leaders speak out against dismissals of Chinese scientists Merck teams up with Themis to develop vaccines Finch raises $53M to push microbiome drug to key readout Chinook Therapeutics bags $65M to bring precision medicine to the kidney Roche's effort to stop cancer metastasis unexpectedly leads to a Merck drug U.S. cancer trials still suffering from lack of diversity: report Featured Story | | | Thursday, August 22, 2019 Firm details on exactly how the U.K. will regulate new medicines are still to be decided after it leaves the EU later this year, but we now know that the regulator won’t be run by Dr. Ian Hudson, who is stepping down after six years in charge. |
|
|
Top Stories Thursday, August 22, 2019 China's theft of intellectual property from the U.S. and other countries isn’t new—remember the Genentech scientists and the GlaxoSmithKline researchers who funneled trade secrets to associates in China and Taiwan? But government crackdown has highlighted another threat, one that could damage U.S. leadership in the life sciences. Thursday, August 22, 2019 Merck has struck a deal to work with Themis Bioscience on vaccine R&D. The agreement sees Merck invest in Themis and commit up to $200 million (€180 million) in milestones to secure vaccines against an undisclosed target. Thursday, August 22, 2019 Finch Therapeutics has raised $53 million to take its treatment for recurrent Clostridium difficile infections through to a potentially pivotal readout. Finch thinks it can win FDA approval if the clinical study generates “compelling results.” Thursday, August 22, 2019 Chinook Therapeutics raised $65 million in series A cash to do for kidney disease what precision medicine has done for cancer treatment. It will use that capital to push several precision medicines for kidney diseases into the clinic by 2021. Thursday, August 22, 2019 Researchers at Roche and the Paul Scherrer Institute have identified a way to prevent the spread of certain cancer cells. Then they discovered that Merck already has a drug in development that may accomplish that feat. Thursday, August 22, 2019 Oncology tests in the U.S. are still failing to adequately represent racial diversity, and more needs to be done to help combat this disparity, according to new research. Resources Sponsored by: Alexander Group From sales headcount and budgets to new product launches and saying “yes” to millennials, hear the top 7 topics that are trending in sales compensation. Sponsored by: Wesco Pharmaceutical Solutions and WBR Insights The regulations and managing processes for hazardous, controlled and rare chemicals and biologics necessary for drug discovery are a huge distraction for R&D labs. Learn from the perspectives of industry executives the pain points and improvements they want in their processes for chemicals and biologics in pharmaceuticals R&D. Sponsored by: Kinaxis Download this life sciences industry spotlight to discover how concurrent planning can help you overcome complex supply chain challenges to drive down costs and improve efficiency. Sponsored by: Patheon, by Thermo Fisher Scientific Patheon, part of Thermo Fisher Scientific, offers advanced API manufacturing technologies such as continuous processing and continuous analytics to deliver high-quality products with well-defined features to meet your timelines and volume requirements. Sponsored by: ICON Understanding the challenges for formulary decision makers and manufacturers. Sponsored by: Veeva This white paper details how leveraging new reporting capabilities, live UAT feedback sessions, and an agile design approach to study builds will save them time and money. Sponsored by: BBK Worldwide The Study Voices survey challenges the myth that physicians won’t refer patients to clinical trials, and it identifies opportunities to engage physicians as partners in the enrollment process. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. Latin America Healthcare Compliance Certificate Program September 23-26, 2019 BioBasics: Biotech For The Non-Scientist Oct 22-23, 2019 | San Diego, CA BioImmersion: Biotech for the Non-Scientist October 23-25, 2019 | Chicago, IL 4th FierceBiotech Drug Development Forum October 28-29, 2019 | Boston, MA Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register NOW and start Pre-Boot Camp Preparation! | 